AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC™ (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan.
- AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization
- Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life
AXS-07 is an investigational drug not approved by the FDA and its safety and effectiveness have not been established.
clinical and regulatory
AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development.
